BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 18268330)

  • 1. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma.
    Ratnacaram CK; Teletin M; Jiang M; Meng X; Chambon P; Metzger D
    Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2521-6. PubMed ID: 18268330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
    Luchman HA; Benediktsson H; Villemaire ML; Peterson AC; Jirik FR
    PLoS One; 2008; 3(12):e3940. PubMed ID: 19081794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
    Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
    PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias.
    Mirantes C; Eritja N; Dosil MA; Santacana M; Pallares J; Gatius S; Bergadà L; Maiques O; Matias-Guiu X; Dolcet X
    Dis Model Mech; 2013 May; 6(3):710-20. PubMed ID: 23471917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma.
    Adisetiyo H; Liang M; Liao CP; Aycock-Williams A; Cohen MB; Xu S; Neamati N; Conway EM; Cheng CY; Nikitin AY; Roy-Burman P
    PLoS One; 2013; 8(7):e69484. PubMed ID: 23936028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
    Ma X; Ziel-van der Made AC; Autar B; van der Korput HA; Vermeij M; van Duijn P; Cleutjens KB; de Krijger R; Krimpenfort P; Berns A; van der Kwast TH; Trapman J
    Cancer Res; 2005 Jul; 65(13):5730-9. PubMed ID: 15994948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.
    Zhong C; Saribekyan G; Liao CP; Cohen MB; Roy-Burman P
    Cancer Res; 2006 Feb; 66(4):2188-94. PubMed ID: 16489020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer induced by loss of Apc is restrained by TGFβ signaling.
    Bjerke GA; Pietrzak K; Melhuish TA; Frierson HF; Paschal BM; Wotton D
    PLoS One; 2014; 9(3):e92800. PubMed ID: 24651496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.
    Kim J; Roh M; Doubinskaia I; Algarroba GN; Eltoum IE; Abdulkadir SA
    Oncogene; 2012 Jan; 31(3):322-32. PubMed ID: 21685943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
    Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
    Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
    Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
    Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
    Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
    Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Controlled PTEN-Knockout Mouse Model for Prostate Cancer Study.
    Liu S; Zhang B; Rowan BG; Jazwinski SM; Abdel-Mageed AB; Steele C; Wang AR; Sartor O; Niu T; Zhang Q
    Front Mol Biosci; 2021; 8():696537. PubMed ID: 34150854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model.
    Hill R; Song Y; Cardiff RD; Van Dyke T
    Cancer Res; 2005 Nov; 65(22):10243-54. PubMed ID: 16288012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.
    Bjerke GA; Yang CS; Frierson HF; Paschal BM; Wotton D
    Oncogene; 2014 Jul; 33(28):3660-7. PubMed ID: 23995785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
    Lu TL; Huang YF; You LR; Chao NC; Su FY; Chang JL; Chen CM
    Am J Pathol; 2013 Mar; 182(3):975-91. PubMed ID: 23313138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
    Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
    Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperation between Stat3 and Akt signaling leads to prostate tumor development in transgenic mice.
    Blando JM; Carbajal S; Abel E; Beltran L; Conti C; Fischer S; DiGiovanni J
    Neoplasia; 2011 Mar; 13(3):254-65. PubMed ID: 21390188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases.
    Abate-Shen C; Banach-Petrosky WA; Sun X; Economides KD; Desai N; Gregg JP; Borowsky AD; Cardiff RD; Shen MM
    Cancer Res; 2003 Jul; 63(14):3886-90. PubMed ID: 12873978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.
    Mi J; Hooker E; Balog S; Zeng H; Johnson DT; He Y; Yu EJ; Wu H; Le V; Lee DH; Aldahl J; Gonzalgo ML; Sun Z
    J Biol Chem; 2018 Dec; 293(52):20123-20136. PubMed ID: 30401749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.